Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.20 -1.6%	$1.28	$0.87 ▼ $2.55	$23M	0.47	218,632 shs	94,544 shs
GOVX GeoVax Labs	$0.94 +2.1%	$1.00	$0.73 ▼ $11.18	$14.05M	3.45	1.21 million shs	2.90 million shs
INDP Indaptus Therapeutics	$0.27 -17.9%	$0.40	$0.27 ▼ $2.42	$5.28M	1.31	222,706 shs	406,791 shs
VTGN VistaGen Therapeutics	$2.00 -2.9%	$2.31	$1.90 ▼ $4.21	$60.06M	0.7	174,249 shs	389,042 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-1.64%	0.00%	-13.04%	-6.25%	+26.58%
GOVX GeoVax Labs	+2.09%	-8.35%	-3.66%	-27.94%	-50.32%
INDP Indaptus Therapeutics	-17.90%	-16.84%	-28.92%	-62.50%	-89.15%
VTGN VistaGen Therapeutics	-2.91%	-9.50%	-17.70%	-28.32%	-39.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	2.5689 of 5 stars	3.5	5.0	0.0	1.7	0.6
GOVX GeoVax Labs	3.1043 of 5 stars	3.6	4.0	2.6	1.7	0.6
INDP Indaptus Therapeutics	2.6938 of 5 stars	3.5	2.0	2.2	1.7	1.3
VTGN VistaGen Therapeutics	1.1478 of 5 stars	0.0	2.0	3.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	608.33% Upside
GOVX GeoVax Labs	3.29	Buy	$11.10	1,075.85% Upside
INDP Indaptus Therapeutics	3.00	Buy	$8.50	3,046.98% Upside
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest GOVX, CMMB, INDP, and VTGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
GOVX GeoVax Labs	$3.95M	3.63	N/A	N/A	$0.48 per share	1.97
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$0.39 per share	N/A
VTGN VistaGen Therapeutics	$490K	119.02	N/A	N/A	$4.23 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.76	N/A	N/A	N/A	N/A	-106.70%	-82.18%	8/20/2025 (Estimated)
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)
INDP Indaptus Therapeutics	-$15.02M	-$1.49	N/A	N/A	N/A	N/A	-333.02%	-216.36%	8/11/2025 (Estimated)
VTGN VistaGen Therapeutics	-$29.36M	-$1.48	N/A	N/A	N/A	-6,777.08%	-58.88%	-52.38%	8/11/2025 (Estimated)

Latest GOVX, CMMB, INDP, and VTGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.53	-$0.43	+$0.10	-$0.43	$0.18 million	($0.01) million
5/15/2025	Q1 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
5/14/2025	Q1 2025	INDP Indaptus Therapeutics	-$0.41	-$0.32	+$0.09	-$0.32	N/A	N/A
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	5.33	5.33
GOVX GeoVax Labs	N/A	3.62	3.62
INDP Indaptus Therapeutics	N/A	1.90	1.90
VTGN VistaGen Therapeutics	N/A	6.51	9.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
GOVX GeoVax Labs	6.09%
INDP Indaptus Therapeutics	7.06%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
GOVX GeoVax Labs	1.20%
INDP Indaptus Therapeutics	20.60%
VTGN VistaGen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
GOVX GeoVax Labs	10	15.19 million	15.01 million	Not Optionable
INDP Indaptus Therapeutics	6	16.03 million	12.73 million	Not Optionable
VTGN VistaGen Therapeutics	40	29.16 million	28.78 million	Optionable

GOVX, CMMB, INDP, and VTGN Headlines

Recent News About These Companies

William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)

June 20 at 3:48 AM | theglobeandmail.com

VistaGen Therapeutics (NASDAQ:VTGN) Earns Outperform Rating from William Blair

June 20 at 1:31 AM | americanbankingnews.com

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

June 19 at 8:25 PM | tipranks.com

What is William Blair's Forecast for VTGN Q1 Earnings?

June 19 at 7:40 AM | marketbeat.com

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair

June 18 at 10:11 PM | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

June 18 at 4:22 AM | finance.yahoo.com

Vistagen Therapeutics Reports Progress in Clinical Trials

June 18 at 12:26 AM | tipranks.com

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

June 17, 2025 | seekingalpha.com

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

June 17, 2025 | marketbeat.com

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17, 2025 | businesswire.com

Insights into VistaGen Therapeutics's Upcoming Earnings

June 16, 2025 | benzinga.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

June 16, 2025 | gurufocus.com

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025 | businesswire.com

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday

June 3, 2025 | marketbeat.com

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?

May 28, 2025 | marketbeat.com

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025 | businesswire.com

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025 | businesswire.com

Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%

April 8, 2025 | aaii.com

VistaGen at Stifel 2025: Pioneering Acute SAD Treatment

March 20, 2025 | investing.com

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

March 19, 2025 | businesswire.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript

February 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX, CMMB, INDP, and VTGN Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$1.20 -0.02 (-1.64%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.20 0.00 (0.00%)

As of 06/20/2025 06:55 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

GeoVax Labs NASDAQ:GOVX

$0.94 +0.02 (+2.09%)

As of 06/20/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Indaptus Therapeutics NASDAQ:INDP

$0.27 -0.06 (-17.90%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.29 +0.02 (+7.37%)

As of 06/20/2025 06:57 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

VistaGen Therapeutics NASDAQ:VTGN

$2.00 -0.06 (-2.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.02 +0.02 (+1.00%)

As of 06/20/2025 07:59 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time